Vortioxetine PK/PD Simulator
Indication: Major Depressive Disorder (MDD)
Interactive PK/PD simulator for vortioxetine (Trintellix) based on population pharmacokinetic-pharmacodynamic meta-analysis in MDD patients. Explore exposure-efficacy (MADRS) and exposure-safety (nausea) relationships.
Drug Overview
Clinical Context
- Drug Class
- Antidepressant (Multimodal)
- Therapeutic Area
- Psychiatry
- Indication
- Major Depressive Disorder (MDD)
- Route of Administration
- Oral
Model Information
- Model Type
- PopPK + Emax PK/PD
- Reference
- Naik et al. 2016, Basic Clin Pharmacol Toxicol 118:344-355
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| Ka | 0.14 hr-1 |
| Q F | 23 L/hr |
PD Parameters
| Parameter | Value |
|---|---|
| E0 | -13.2 |
| EC50 | 24.9 ng/mL |
| Emax | 7.0 MADRS points |
Additional Parameters
| Parameter | Value |
|---|---|
| V2 F | 2900 L |
| V3 F | 670 L |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Vortioxetine allows you to explore concentration-time profiles under different dosing scenarios. The underlying PopPK + Emax PK/PD model characterizes the pharmacokinetics of this antidepressant (multimodal) following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Vortioxetine PK simulator?
This is a free, interactive pharmacokinetic simulator for Vortioxetine used in Major Depressive Disorder (MDD). It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Vortioxetine belong to?
Vortioxetine is classified as a Antidepressant (Multimodal). It is used in the Psychiatry therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Vortioxetine. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PopPK + Emax PK/PD model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of Vortioxetine?
Based on the published model parameters, the elimination half-life of Vortioxetine is approximately ~57 hr. Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
Related Simulators
Ready to Simulate?
Launch the Vortioxetine simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community